New
Trackinsight is part of ETF One, the fully integrated ETF platform of Kepler Cheuvreux. Learn more →
Help us improve your experience. Please confirm your investor type:
ETF What's Up
Don’t Miss a Move in the ETF Market
Sign up and keep track of everything that moved the ETF industry this week. From new launches to regulatory shifts across the Atlantic.
SBIO ETF · Invesco NASDAQ Biotech UCITS ETF
The SBIO Exchange Traded Fund (ETF) is provided by Invesco. It is built to track an index: NASDAQ Biotechnology Index. This ETF provides synthetic exposure, by owning its shares you earn the return of the index indirectly through the use of derivatives or a swap (i.e. a contract with a financial institution which delivers the return of the index). The dividend policy is capitalization.
Last update Today at 7:00 AM UTC
LIVE
CLOSED
This fund is part ofUS Health Care1M perf.-6.30%
Last price
$61.41
1M perf.
-0.56%
1M flows
-€5.1M
AuM
€365M
E/R
0.4%
Rating
ESG Consensus®
SBIO
$61.41
Performance & flows
Segment for quartile rank
December 31, 2025 → March 31, 2026
Create a free account to view the flows graph
SBIO
$60.79
+2.36%
US Health Care
-3.69%
Historic performance and flows
| 1M | 3M | 1Y | 3Y | 5Y | MTD | QTD | YTD | ||
|---|---|---|---|---|---|---|---|---|---|
| Perf. | -0.56%  | +2.36% | +37.99% | +43.19% | +26.00% | -3.31% | +2.36% | +2.36% | |
| Flows |
Key fund info
Segment for quartile rank
Main characteristics
More details
NAV
3/31/2026
$60.79
1D NAV change
+4.57%
Dividend policy
Replication method
Indirect
Replication model
Unfunded swap
No. of holdings
260
Inception date
11/7/2014
Jurisdiction
Ireland
Distribution
Luxembourg
Switzerland
Liechtenstein
Austria
Italy
Legal structure
Open-end Investment Company
Base currency
USD
Classification
Investment strategy
The Invesco NASDAQ Biotech UCITS ETF Acc aims to provide the performance of the NASDAQ Biotechnology Index, after fees. The index comprises biotechnology and pharmaceuticals companies (as defined by ICB) listed on the NASDAQ Stock Market. Stocks are filtered to meet minimum market capitalisation and liquidity requirements. They are then weighted by modified market capitalisation: the largest five constituents are capped at 8%; the remaining constituents are capped at 4%. The index is rebalanced quarterly and reviewed annually in December.
Tax optimisation
PEA
France
UK Reporting Status
United Kingdom
Create a free Trackinsight Essentials account to unlock insights
Access exclusive metrics and features to support your investment decisions.
Built for professionals: access exclusive fund metrics and selection tools in Trackinsight Enterprise.
Enterprise Fund page features include:
Legal documents
Powerful buy-list integration
Fund data exports
Advanced risk metrics
Advanced replication analysis
Advanced exposure look-through
Upload your own internal metrics
Custom data feature
Enterprise
Trackinsight Enterprise helps professional and institutional ETF investors tackle operational, regulatory, and analytical challenges at every stage of the investment process.
Learn more about Trackinsight EnterpriseAdvertisement
Risk profile
Segment for quartile rank
Historical risk/return profile
| 3M | 1Y | 3Y | 5Y | |
|---|---|---|---|---|
| Returns | +2.36% | +37.99% | +43.19% | +26.00%  |
| Volatility | ||||
| Perf./Volatility | ||||
| Max drawdown |
Create a free account to view risk/return table
Synthetic Risk and Reward Indicator (SRRI)
UCITS
1
2
3
4
5
6
7
PRIIPS
1
2
3
4
5
6
7
More exposure metrics are available, exclusively in Trackinsight Enterprise
Exposure
Exposure based on a proxy
More info
Countries
USA
93.06%
United Kingdom
1.60%
Bermuda
1.49%
Ireland
1.36%
Unavailable
0.19%
Other
2.30%
Sectors
Health Care
86.31%
Unavailable
13.67%
Diversification
Exposure based on a proxy
More info
Total weight of top 15 holdings out of 260
Top 15 holdings
Data as of February 28, 2026
Exposure based on a proxy
More info
GILEAD SCIENCES
VERTEX PHARMACEUTICALS
AMGEN-T
REGENERON PHARMACEUTICALS
ALNYLAM PHARMACEUTICALS
INSMED
BIOGEN INC
US04016X1019
Create a free account to view top holdings
UTD THERAPEUT
MODERNA INC
ROIVANT SCIENCES LTD
REVOLUTION MEDICINES INC
INCYTE
ILLUMINA
ROYALTY PHARMA
Create a free account to view top holdings
More risk metrics are available, exclusively in Trackinsight Enterprise
Sustainability
Integrates ESG criteria
No
SDG
More sustainability metrics are available, exclusively in Trackinsight Enterprise
Replication
Trackinsight replication rating:
Replication quality
Calculated over 12m, as of March 31, 2026
Tracking error
Tracking difference
Replication information
Index
NASDAQ Biotechnology Total Return Index - USD
Index ticker
XNBI Index
Index dividend policy
GTR
Replication method
Replication model
More replication analysis are available, exclusively in Trackinsight Enterprise
Issuer
Invesco
Invesco ID Card
Number of funds
633
Total AuM
€825.07B
Expense ratio range
0.04% - 5.39%
Average expense ratio
0.3558%
Top 5 funds by Invesco
| AuM | ||
|---|---|---|
QQQ | Invesco QQQ ETF | €321.23B |
RSP | Invesco S&P 500® Equal Weight ETF | €73.76B |
QQQM | Invesco NASDAQ 100 ETF | €59.66B |
SPXS | Invesco S&P 500 UCITS ETF | €29.41B |
SGLD | Invesco Physical Gold USD ETC | €25.46B |
Frequently asked questions about SBIO
What does Invesco NASDAQ Biotech UCITS ETF, SBIO, invest in?
SBIO is a Passive ETF. This ETF provides exposure to US Equities.
Which benchmark or index does SBIO replicate?
SBIO tracks the NASDAQ Biotechnology Total Return Index - USD, through a unfunded swap replication method.
What is the Total Expense ratio (TER) of SBIO?
SBIO carries a total expense ratio (TER) of 0.4%, indicating the annual cost for holding the fund.
When was SBIO launched?
SBIO was introduced to the market on November 7, 2014. It trades on Luxembourg, among other exchanges
Who is the ETF issuer of SBIO?
Invesco NASDAQ Biotech UCITS ETF, SBIO, is provided by Invesco. Learn more about Invesco here.
What is the current assets under management (AUM) of SBIO?
SBIO oversees €365M in assets as of March 31, 2026.
How has SBIO performed lately?
Based on data from March 31, 2026, SBIO returned -0.56% over the past month, 2.36% over the last three months and 2.36% year-to-date.
What are the latest inflows or outflows for SBIO?
As of March 31, 2026, SBIO recorded net flows of -€5M over the last month and -€11M year-to-date.
Does SBIO distribute dividends?
SBIO follows a capitalizing, meaning it reinvests income within the fund.
What are the main country or region exposures of SBIO?
As of February 28, 2026, SBIO has significant geographic allocations in USA, United Kingdom and Bermuda.
In which sector or theme does SBIO invest in?
As of February 28, 2026, SBIO focuses largely on Health Care.
How many securities does SBIO hold and how diversified is it?
As of February 28, 2026, SBIO holds 260 positions in its portfolio, with 53.32% of assets concentrated in its top 15 holdings.
What are the main positions in SBIO?
As of February 28, 2026, SBIO top three holdings include GILEAD SCIENCES, VERTEX PHARMACEUTICALS and AMGEN-T.
What is the base currency of SBIO?
The base currency of SBIO is USD.
Advertisement
About Trackinsight
Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.
Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.
In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.
This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.
Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.
More about TrackinsightETF TOOLS
PLATFORM
ETF NEWS & RESEARCH
© 2014-2026 Trackinsight SA. All rights reserved.
Privacy policy | Cookie policy | | Terms of use | Imprint
Privacy policy | Cookie policy | | Terms of use | Imprint
